RxDoctor Payments Data

Stephanie Farmer

Family · Bryant, ARNPI 1518982305

Payments from drug & device makers

$5,921in general payments, 2019–2025

Across 377 payments — averaging $15.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$553
  • AstraZeneca$493
  • Boehringer Ingelheim$398
  • Novo Nordisk$350
  • Dexcom, Inc.$306
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$5,921100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,921 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$82,963
Medicare patients
222
Services billed
1,909

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide114$127,850
MounjaroTirzepatide59$62,151
JardianceEmpagliflozin57$51,844
TrulicityDulaglutide22$28,333
JanuviaSitagliptin Phosphate29$24,792
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$18,026
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog21$17,189
EliquisApixaban11$16,537
XareltoRivaroxaban18$13,736
Tresiba Flextouch U-200Insulin Degludec11$13,263
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$10,387
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$9,294
FarxigaDapagliflozin Propanediol16$9,139
TradjentaLinagliptin12$6,069
BelsomraSuvorexant13$5,732

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$350$127,850114 claims
Lilly USA, LLCMounjaro, Trulicity$241$90,48481 claims
Boehringer IngelheimJardiance, Tradjenta$398$57,91369 claims
MerckJanuvia, Belsomra$36$30,52442 claims
AstraZenecaBreztri Aerosphere, Farxiga$493$18,43330 claims
GSKTrelegy Ellipta$116$18,02620 claims
PfizerEliquis$144$16,53711 claims
Johnson & JohnsonXarelto$80$13,73618 claims
AbbVieSynthroid$1,462$1,50215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.

Other family in Bryant

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →